Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SUPN
  • CUSIP: 86845910
  • Web:
  • Market Cap: $1.8 billion
  • Outstanding Shares: 50,282,000
Average Prices:
  • 50 Day Moving Avg: $32.80
  • 200 Day Moving Avg: $27.44
  • 52 Week Range: $17.25 - $36.05
  • Trailing P/E Ratio: 19.23
  • Foreward P/E Ratio: 22.20
  • P/E Growth: 1.18
Sales & Book Value:
  • Annual Revenue: $228.39 million
  • Price / Sales: 7.87
  • Book Value: $4.10 per share
  • Price / Book: 8.72
  • EBIDTA: $67.28 million
  • Net Margins: 43.38%
  • Return on Equity: 35.33%
  • Return on Assets: 18.67%
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 1.93%
  • Quick Ratio: 1.69%
  • Average Volume: 616,581 shs.
  • Beta: 1.89
  • Short Ratio: 3.68

Frequently Asked Questions for Supernus Pharmaceuticals (NASDAQ:SUPN)

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) posted its earnings results on Tuesday, May, 9th. The company reported $0.19 EPS for the quarter, missing the Zacks' consensus estimate of $0.22 by $0.03. The business earned $57.58 million during the quarter, compared to the consensus estimate of $57.91 million. Supernus Pharmaceuticals had a return on equity of 35.33% and a net margin of 43.38%. View Supernus Pharmaceuticals' Earnings History.

Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?

6 brokers have issued twelve-month price objectives for Supernus Pharmaceuticals' stock. Their predictions range from $23.00 to $36.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $29.83 in the next twelve months. View Analyst Ratings for Supernus Pharmaceuticals.

What are analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:

  • 1. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "SUPN announced the settlement of a Paragraph 4 challenge to Trokendi XR patents by Zydus allowing generic entry on or before 1/1/2023." (3/7/2017)
  • 3. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (3/4/2017)

Who are some of Supernus Pharmaceuticals' key competitors?

Who owns Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.35%), Vanguard Group Inc. (5.02%), Bank of New York Mellon Corp (3.33%), Acadian Asset Management LLC (3.23%), Ranger Investment Management L.P. (2.96%) and State Street Corp (2.70%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, M James Barrett, Padmanabh P Bhatt, Scott D Sandell and Stefan KF Schwabe. View Institutional Ownership Trends for Supernus Pharmaceuticals.

Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Ameriprise Financial Inc., Morgan Stanley, Northpointe Capital LLC, Alliancebernstein L.P., Lazard Asset Management LLC, Eventide Asset Management LLC and Franklin Street Advisors Inc. NC. Company insiders that have sold Supernus Pharmaceuticals stock in the last year include Gregory S Patrick and Padmanabh P Bhatt. View Insider Buying and Selling for Supernus Pharmaceuticals.

Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., AXA, Vanguard Group Inc., Royce & Associates LP, BNP Paribas Arbitrage SA, Ashford Capital Management Inc., Gotham Asset Management LLC and Neumeier Poma Investment Counsel LLC. View Insider Buying and Selling for Supernus Pharmaceuticals.

How do I buy Supernus Pharmaceuticals stock?

Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Supernus Pharmaceuticals stock cost?

One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $35.75.

Analyst Ratings

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $29.83 (16.55% downside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Cantor FitzgeraldBoost Price TargetOverweight$25.00 -> $27.00LowView Rating Details
5/11/2017Cowen and CompanyBoost Price TargetOutperform$31.00 -> $34.00LowView Rating Details
5/10/2017Jefferies Group LLCSet Price TargetBuy$35.00LowView Rating Details
4/3/2017Stifel NicolausBoost Price TargetBuy$30.00 -> $36.00LowView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
7/18/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$23.00N/AView Rating Details
6/12/2015SunTrust Banks, Inc.Initiated CoverageBuy$30.00N/AView Rating Details
6/9/2015GuggenheimInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings History by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.22$0.19$57.91 million$57.58 millionViewListenView Earnings Details
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
2017 EPS Consensus Estimate: $1.04
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.16$0.24$0.20
Q2 20172$0.19$0.24$0.22
Q3 20171$0.25$0.25$0.25
Q4 20172$0.26$0.49$0.38
(Data provided by Zacks Investment Research)


Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 94.94%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017Padmanabh P BhattVPSell5,500$34.90$191,950.00View SEC Filing  
4/24/2017Gregory S PatrickCFOSell54,000$32.37$1,747,980.00View SEC Filing  
4/24/2017Padmanabh P BhattVPSell11,806$32.59$384,757.54View SEC Filing  
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.00View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Supernus Pharmaceuticals (NASDAQ:SUPN)
Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateHeadline logoSupernus Pharmaceuticals Inc (SUPN) VP Sells $191,950.00 in Stock - May 25 at 10:21 PM logoEdited Transcript of SUPN earnings conference call or presentation 10-May-17 1:00pm GMT - May 16 at 8:54 AM logoSunTrust Banks Weighs in on Supernus Pharmaceuticals Inc's Q2 2017 Earnings (SUPN) - May 15 at 7:26 AM logoSupernus Pharmaceuticals Inc (SUPN) Receives Consensus Rating of "Buy" from Analysts - May 12 at 2:38 PM logoEquities Analysts Issue Forecasts for Supernus Pharmaceuticals Inc's FY2017 Earnings (SUPN) - May 12 at 12:32 PM logoSupernus Pharmaceuticals Inc (SUPN) Stock Rating Reaffirmed by Cantor Fitzgerald - May 11 at 9:02 PM logoCowen and Company Reiterates Outperform Rating for Supernus Pharmaceuticals Inc (SUPN) - May 11 at 4:46 PM logoJefferies Group LLC Reiterates $35.00 Price Target for Supernus Pharmaceuticals Inc (SUPN) - May 11 at 2:56 PM logoSupernus Pharmaceuticals Inc (SUPN) Expected to Earn FY2017 Earnings of $0.87 Per Share - May 11 at 10:52 AM logoSupernus Pharmaceuticals Inc (SUPN) Issues Earnings Results, Misses Estimates By $0.03 EPS - May 10 at 6:20 PM logoInvestor Network: Supernus Pharmaceuticals, Inc. to Host Earnings Call - May 10 at 10:32 AM logoJefferies Group Weighs in on Supernus Pharmaceuticals Inc's Q1 2017 Earnings (SUPN) - May 10 at 7:48 AM logoSupernus Announces First Quarter 2017 Financial Results - May 9 at 7:33 PM logoSupernus misses Street 1Q forecasts - May 9 at 4:40 PM logoSupernus Pharmaceuticals, Inc. (SUPN) - May 8 at 10:52 AM logoEquities Analysts Set Expectations for Supernus Pharmaceuticals Inc's Q1 2017 Earnings (SUPN) - May 8 at 7:27 AM logoSupernus Pharmaceuticals (SUPN) Earning Favorable Press Coverage, Analysis Shows - May 5 at 10:57 PM logoSupernus Pharmaceuticals Inc (SUPN) Expected to Announce Earnings of $0.21 Per Share - May 3 at 9:43 AM logoSupernus Pharmaceuticals (SUPN) Getting Somewhat Favorable News Coverage, AlphaOne Reports - May 2 at 8:16 PM logoSupernus Pharmaceuticals (SUPN) Given News Sentiment Score of -0.03 - April 29 at 3:35 PM logoInsider Selling: Supernus Pharmaceuticals Inc (SUPN) CFO Sells 54,000 Shares of Stock - April 26 at 8:21 PM logoSupernus Pharmaceuticals (SUPN) Given Daily Media Impact Rating of 0.17 - April 26 at 7:38 PM logoSupernus to Host First Quarter 2017 Earnings Conference Call - April 26 at 4:30 PM logoSupernus Pharmaceuticals (SUPN) Earns Media Sentiment Score of 0.31 - April 23 at 7:00 PM logoThis Biotech Leader Breaks Out, Defying Sector Odds - April 18 at 7:15 PM logoSupernus Pharmaceuticals Inc (SUPN) Receives Average Recommendation of "Buy" from Brokerages - April 17 at 5:08 PM logoSupernus Pharmaceuticals (SUPN) Receives Media Sentiment Rating of 0.56 - April 17 at 10:33 AM logoPositive News Coverage Unlikely to Impact Supernus Pharmaceuticals (SUPN) Share Price - April 14 at 7:09 PM logoSupernus Pharmaceuticals' (SUPN) Buy Rating Reaffirmed at Jefferies Group LLC - April 14 at 3:10 PM logoZacks: Analysts Anticipate Supernus Pharmaceuticals Inc (SUPN) Will Post Quarterly Sales of $59.18 Million - April 14 at 2:40 PM logoSupernus Pharmaceuticals Inc (SUPN) Given Overweight Rating at Cantor Fitzgerald - April 13 at 7:20 AM logoSupernus Pharmaceuticals Inc (SUPN) Expected to Announce Earnings of $0.22 Per Share - April 12 at 7:53 AM logoSupernus Pharmaceuticals Inc (SUPN) Rating Reiterated by Cantor Fitzgerald - April 7 at 5:50 PM logoSupernus Pharma (SUPN) Granted Final FDA Approval for Trokendi XR® for Migraine Prophylaxis - April 7 at 12:51 PM logoSupernus Drug Gets Label Expansion for Migraines (SUPN) - April 7 at 12:51 PM logoCommit To Purchase Supernus Pharmaceuticals At $26, Earn 15.3% Annualized Using Options - April 7 at 12:51 PM logoSupernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents - April 7 at 12:51 PM logoSupernus Drug Gets Label Expansion for Migraines - April 7 at 12:51 PM logoSupernus Pharmaceuticals Inc (SUPN) Rating Reiterated by Stifel Nicolaus - April 3 at 2:34 PM logoSupernus Pharmaceuticals Inc (SUPN) Given Consensus Recommendation of "Buy" by Analysts - March 22 at 12:46 PM logoSupernus Pharmaceuticals (SUPN) Presents At Cowen and Company 37th Annual Health Care Conference - Slideshow - March 9 at 1:37 AM logoSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial - March 8 at 8:37 PM logoSupernus Pharmaceuticals Inc (SUPN) PT Raised to $35.00 at Jefferies Group LLC - March 8 at 8:32 PM logoAXSM Looks To Busy Year Ahead, SUPN Makes Peace Again ... - RTT News - March 8 at 8:04 AM logoSupernus Pharma Tanks on Settlement of Two Patent Disputes (SUPN) - March 8 at 8:04 AM logoSupernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation - March 7 at 7:56 PM logoETFs with exposure to Supernus Pharmaceuticals, Inc. : March 6, 2017 - March 6 at 7:18 PM logoSupernus Announces Settlement with Zydus on Trokendi XR® Patent Litigation - March 6 at 7:18 PM logoEdited Transcript of SUPN earnings conference call or presentation 1-Mar-17 2:00pm GMT - March 1 at 10:55 PM logoSupernus Announces Record Fourth Quarter and Full Year 2016 Financial Results - March 1 at 9:40 AM



Supernus Pharmaceuticals (SUPN) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff